There is a new product available to help overcome blinding challenges in trials that makes it possible to administer a study drug without participants knowing whether they’re receiving the investigational product or placebo.

Lonza’s Capsugel DBcaps feature an anti-tampering, double-layer design that allows investigators to over-encapsulate drug and placebo products opaquely and offer high visual coverage of what is placed inside. The capsules could improve the cost efficiency of trials, as they reduce the need for companies to produce placebo forms that are identical in size and shape to the candidate drug.